Our production facility in Leiden

Our new production centre in Leiden will bring CAR T cell therapy closer to cancer patients in Europe.

Bristol Myers Squibb chose the Leiden Bio Science Park as the European location for a new CAR T cell therapy facility. With this new facility, we are investing in the expansion of our global network to bring cell therapy closer to patients with blood cancers in Europe.


This production centre is our first European site where we plant our BMS flag and will be our fifth facility worldwide working on the development of cell therapy. The facility will be equipped with the latest technology and manufacturing equipment. The construction work has started in autumn 2021 and the site is expected to be completed and operational by the end of 2024.


With this new production centre, we are contributing to the growing role of the Netherlands as an international leader in the field of CAR T cell therapy.


What is CAR T?

CAR T stands for 'Chimeric Antigen Receptor T-cell' therapy. T-cells are immune cells that can attack and eliminate malignant cancer cells. White blood cells are taken from cancer patients who qualify for this therapy. These are genetically modified in our CAR T cell therapy facility and then administered back to the patient in specialised centres. This treatment helps to fight hematological cancers via the body's own T-cells.

Do you want to help patients? Come and work with us!  


We want to build the future of healthcare innovation in the Netherlands, Europe and beyond with you. Innovation is an integral part of us that requires a pioneering spirit.

Integrity, Innovation, Urgency, Passion, Responsibility, and Inclusion is our DNA. We are committed to your growth and offer fascinating new challenges every day.

Visit our career page

We are looking for passionate people who want to help build - literally and figuratively - better care to make a difference for patients. And you can contribute to that.


Leiden Bio Science Park


The Netherlands has everything that's needed to become the pharmaceutical hub of Europe, the 'Boston by the North Sea'. 

Leiden Bio Science Park (LBSP) is the largest innovation district in the Netherlands in the field of Life Sciences & Health. The region offers a stimulating international community for innovation, cooperation and is a dynamic environment for life science professionals. In addition, transport connectivity is very important to us because of our work transporting patient cells. With the nearby airports of Schiphol and Rotterdam, Leiden is an ideal location.


The people who work, live and reside at LBSP feel connected by one common mission: to contribute to the development of new medicines and the improvement of people's health through knowledge and innovation. LBSP also organises numerous events, workshops, sports and cultural activities.


Kaart van Nederland

The Leiden facility is growing

Start of the construction work from above

Virtual BMS Cell Therapy Manufacturing Tour

Planting a flag in our first European CAR T facility

Celebration of the Topping Off ceremony

Global Impact in Health Symposium at the LBSP


On the 30th of May 2022, the Global Impact in Health Symposium opened the Life Science & Health Week in Leiden.


The  Symposium brought together the life science community to think through ways of improving some of our most critical health dilemmas globally, including diversity and health equity. Anne Kerber, Senior VP and Head of Cell Therapy Development at Bristol Myers Squibb, gave a keynote about the importance of equity and diversity in clinical trials to deliver better science and outcomes for patients.

Leiden productiefaciliteit
Leiden Bio Science Park